期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

42例利妥昔单抗药品不良反应/事件报告分析 被引量：11

Analysis on 42 Cases of Adverse Drug Reaction/Event Induced by Rituximab
下载PDF
导出
摘要 采用回顾性研究方法,对42例利妥昔单抗药品不良反应/事件(ADR/ADE)报告进行综合分析:有20例是急性输注反应,其中发生过敏性休克3例;血液系统、皮肤及附件损害各6例;肝损害5例;胃肠道损害3例,含1例出现胃肠穿孔;肾功能异常、高血压加重各1例。利妥昔单抗可引起严重ADR/ADE,须加强该药ADR/ADE的研究及防治。 A total of 42 adverse drug reactions/event （ADR/ADE） reports induced by rituximab in Jiangsu province were analyzed in order to investigate the epidemiological characteristics of ADR/ADE induced by rituximab. Among the ADR/ADE, 20 cases were acute infusion reactions, included three allergic shock cases; six cases in each were blood system lesions and the skin and appendages lesions; five cases were liver damages; three cases were gastrointestinal lesions, included one gastrointestinal perforation; one fbr each were renal dysfunction and increased hypertension. It should toe strengthened the observation and evaluation of rituximab ADR/ADE.
作者 甘戈 孙骏
机构地区 江苏省药品不良反应监测中心
出处 《药学与临床研究》 2012年第1期80-83,共4页 Pharmaceutical and Clinical Research
关键词 利妥昔单抗 急性输注反应 血液系统损害 肝损害 药品不良反应 Rituximab Infusion Reactions Blood system lesions Liver damage： Adverse drug reactions
分类号 R969.3 [医药卫生—药理学]
  • 相关文献

参考文献13

  • 1Lim I.C, Koh LP, Tan P. Fatal cytokine release syndrome with chimeric anti-CD20 monoclonal antibody rituximab in a 71-year-old patient with chronic lymphocytic leukemia[J]. J Clin Oncol, 1999, 17(6): 1962-3.
  • 2Reports of Bowel Obstruction and Gastrointestinal Perforation with RITUXAN (rituximah)[EB/OL].[2008-4- 28] http://www.hc-sc.gc.ca/dhp-mps/medeff/advisoriesavis/prof/_2006/rituxan 3 hpc-cps-eng.php, http://www. hc -sc.gc.ca/dhp -mps/medeff/advisories -avis/pro f/_2006/ fituxan_3_hpc-eps-eng.php.
  • 3Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project[J]. Blood, 2009, 113(20): 4834-40.
  • 4季冬梅,曹军宁,洪小南,孙慧,李军民,王健民,陈芳源,王椿,邹善华.类RCHOP方案治疗弥漫大B细胞淋巴瘤后乙型肝炎病毒的激活情况:一项多中心回顾性研究[J].肿瘤,2010,30(7):608-612. 被引量：8
  • 5National Cancer Institule. Common Terminology Criteria for Adverse Events v3.0. (CTCAE)[EB/OL]. 2006-07-07 [2006-08-09]. http://ctep.cancer.gov/fonns/CTC AEv3.pdf.
  • 6Vogel WH. Infusion reactions: diagnosis, assessment, and management[J]. Clin J Otwol Nurs, 2010, 14(2): 10-21.
  • 7Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions [J]. Oncologist, 2007, 12 (5): 601-9.
  • 8田昱平,姚亚洲,彭飞.利妥昔单抗联合常规化疗治疗B细胞淋巴瘤随机对照试验的Meta分析[J].中国肿瘤生物治疗杂志,2011,18(1):63-69. 被引量：9
  • 9Lanini S, Molloy AC, Fine PE, et al. Risk of infection in patients with lymphoma receiving rituximab: system- atic review and meta-analysis [J]. BMC Med, 2011, 12 (9): 36-50.
  • 10Diaz-Lagares C, Perez-Alvarez R, Garcia-Hernandez FJ, et al. Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label [J]. Arthritis Res Ther, 2011, 13(4): R112.

二级参考文献61

  • 1林桐榆,张红雨,黄岩,管忠震,沈悌,石远凯,朱军,克晓燕,王华庆,沈志祥,于世英,刘霆,施笑利.R-CHOP与CHOP方案治疗初治弥漫大B细胞型淋巴瘤在中国的多中心随机对照研究[J].癌症,2005,24(12):1421-1426. 被引量：47
  • 2LEE W.Hepatitis B virus infection[J].N Engl J Med,1997,337(24):1733-1745.
  • 3WANG F,XU R H,HAN B,et al.High incidence of hepatitis B infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers[J].Cancer,2007,109(7):1360-1364.
  • 4CHENG A L,HSIUNG C A,SU I J,et al.Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma[J].Hepatology,2003,37(6):1320-1328.
  • 5YEO W,CHAN K S,ZHONG S,et al.Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy:a prospective study of 626 patients with identification of risk factors[J].J Med Virol,2000,62(3):299-307.
  • 6NAKAMURA Y,MOTOKURA T,FUJITA A,et al.Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies.Survey in Japan,1987-1991[J].Cancer,1996,78(10):2210-2215.
  • 7COIFFIER B,LEPAGE E,BRIERE J,et al.CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma[J].N Engl J Med,2002,346(4):235-242.
  • 8PFREUNDSCHUH M,TRUMPER L,OSTERBORG A,et al.CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma:A randomised controlled trial by the MabThera International Trial (MInT) Group[J].Lancet Oncol,2006,7(5):379-391.
  • 9HABERMANN T M,WELLER E A,MORRISON V A,et al.Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma[J].J Clin Oncol,2006,24(19):3121-3127.
  • 10DERVITE I,HOBER D,MOREL P.Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab[J].N Engl J Med,2001,344(1):68-69.

共引文献31

同被引文献94

  • 1林桐榆,张红雨,黄岩,管忠震,沈悌,石远凯,朱军,克晓燕,王华庆,沈志祥,于世英,刘霆,施笑利.R-CHOP与CHOP方案治疗初治弥漫大B细胞型淋巴瘤在中国的多中心随机对照研究[J].癌症,2005,24(12):1421-1426. 被引量：47
  • 2计成阜,孙爱宁,金正明.输注美罗华引发严重不良反应1例[J].实用医学杂志,2006,22(16):1875-1875. 被引量：9
  • 3CAROLlNE C, CHARLES K L, DAVID I. Systemic lupus erythematosus [J]. Medicine, 20 I 0, 38(2): 73-80.
  • 4SHU M F, MESH S D, FELl CIA G. Pathogenesis of systemic lupus erythematosus revisited 20 11: End organ resistance to damage, autoantibody initiation and diversification, and HLA-DR [J].J Autoimmunity, 2011, 37(2): 104-112.
  • 5LIN, H L, YENJ H, CHOU S S, et al. Estradiol up regulates calcine urine expression via over expression of estrogen receptor alpha gene in systemic lupus erythematosus [J]. KaohsiungJ Med Sci, 2011, 27(4): 125-131.
  • 6MARIANA P, SIMONE A. The role of tumor necrosis factor-alpha (TNF-a) in the pathogenesis of systemic lupus erythematosus [J]. Cytokine, 2011, 56(3): 537-543.
  • 7SALLOUM R, NIEWOLD T B. Interferon regulatory factors in human lupus pathogenesis [J]. Transl Res, 2011, 157(6): 326-331.
  • 8ROBERT G L. Systemic lupus Erythematosus [M]. 5th Ed. US: Academic Press, 2010: 1045-1060.
  • 9BLUMENFELD Z, MISCHARI 0, SCHULTZ N, et al. Gonadotropin releasing hormone agonists may minimize cyclophosphamide associated gonadotoxicity in SLE and autoimmune diseases [J]. Semin Arthritis Rheum, 2011, 41(3): 346-352.
  • 10RADOMIR N, DIJANAJ, STEVAN P, et al. Cyclosporine versus azathioprine therapy in high-risk idiopathic membranous nephropathy patients: A 3-year prospective study [J]. Biomed Pharm, 2011 65(2): 105-110.

引证文献11

二级引证文献40

药学与临床研究
2012年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部